Biomea Fusion reports Phase 1 weight‑loss data for oral GLP‑1 candidate BMF‑650
+1 new source since this summary was written
Biomea Fusion disclosed results of its Phase 1 GLP‑131 trial of BMF‑650, an oral small‑molecule GLP‑1 agonist. In outpatient cohorts 1‑4, mean weight loss at Day 29 ranged from 1.5 % to 3.2 % versus 0.1 % for pooled placebo. A confined fifth cohort achieved a mean loss of 6.1 % (about 6.2 kg) after a rapid titration to 400 mg daily. No severe or serious adverse events were reported, and the company announced a conference call to discuss the data.
Why it matters
The company said the data support pursuing a strategic partnership or licensing deal for later‑stage development. Investors may view the early efficacy and tolerability as a catalyst for future financing or partnership activity.
Key facts
- 1Mean weight reduction in Cohorts 1‑4 at Day 29 ranged from 1.5 % to 3.2 %. stocktitan.net
- 2Pooled placebo participants lost 0.1 % of body weight at Day 29. stocktitan.net
- 3The confined Cohort 5 showed a mean weight loss of 6.1 % (approximately 6.2 kg) at Day 29. investing.com
- 4All treatment‑emergent adverse events across the five active‑dose cohorts were mild or moderate; no severe or serious events occurred. stocktitan.net
- 5The company will hold a conference call on October 13, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). stocktitan.net
Summary written by AlphAI AI Desk from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.